


Topical Naltrexone Treatment for Non-Healing Diabetic Foot Ulcers

ID# 2009-3563



PennState



Efficacy of NTX to Heal Wounds in Rats

Technology Summary

For diabetic patients, non-healing foot ulcers are common and can result in complications (worsening of the ulceration, systemic infection, severe pain, amputation). This technology is a topical administration of naltrexone (NTX) dissolved in a cream, to continuously block the Opioid Growth Factor Receptor sites on wounded tissue. Animal studies show a 25-30% reduction in time for wound healing with NTX. This approach to wound healing specifically enhances new cell replication by increasing DNA synthesis resulting in increased angiogenesis and granulation in epithelial tissue, as well as reducing complications such as infection related to delayed wound closure. NTX accelerates wound closure both in diabetic and non-diabetic patients, making it an optimal treatment to increase the effectiveness of wound repair throughout the population.

Application & Market Utility

There are 26 million diabetics and 86 million pre-diabetics in the U.S. There is 285 million diabetics worldwide. 4.5 million diabetics develop DFUs annually with a U.S. DFU healthcare cost exceeding \$20B annually. The current treatment is costly, has side effects, and carries risk of death following long use. Over-the-counter bandages and creams are ineffective. Topical application of NTX provides fast, inexpensive and safe treatment to accelerate closure of cutaneous wounds. End users: diabetics, healthy individuals, and veterinary practitioners.

Next Steps

Seeking research collaboration and licensing opportunities.

TECHNOLOGY READINESS LEVEL

4-7

Seeking

Investment | Licensing | Research

Keywords

- diabetes
- diabetic foot ulcers
- diabetes complications
- wound healing
- wound treatment

Researchers

Patricia McLaughlin, D.Ed.

Lead Researcher

[Website](#)

Joseph W. Sassani, M.D.

Research Partner

Ian S. Zagon, Ph.D

Research Partner

Originating College

College of Medicine

Office of Technology Management Contact

Long, Melissa

mkl137@psu.edu

814-865-5730



Invent Penn State is a Commonwealth-wide initiative to spur economic development, job creation, and student career success. Invent Penn State blends entrepreneurship-focused academic programs, business startup training and incubation, funding for commercialization, and university-community collaborations to facilitate the challenging process of turning research discoveries into valuable products and services that can benefit Pennsylvanians and humankind. Learn more at invent.psu.edu.

Penn State is an equal opportunity, affirmative action employer, and is committed to providing employment opportunities to all qualified applicants without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability or protected veteran status.